2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-EP02.12

EP02.12 - Ke-Jun Liu

Pdf Summary

The document outlines a study conducted at The Tenth Affiliated Hospital, Southern Medical University, China, assessing the efficacy and safety of nivolumab plus ipilimumab in elderly patients with advanced non-small-cell lung cancer (NSCLC). The study retrospectively analyzed data from May 2022 to December 2023, including five male patients aged 62 to 84 years. The patients, diagnosed with either squamous cell carcinoma or adenocarcinoma, were given nivolumab plus ipilimumab as initial or second-line therapy. This regimen was chosen as older patients often cannot tolerate the side effects of traditional chemotherapy.<br /><br />The primary endpoint was the objective response rate (ORR), with secondary endpoints including disease control rate (DCR), progression-free survival (PFS), and treatment-related toxicity. The key findings showed that all patients achieved a partial response, leading to an ORR and DCR of 100%. The median PFS was not reached, indicating particularly effective disease control. Only one patient experienced disease progression. <br /><br />Regarding safety, the treatment was well-tolerated, with no grade 3 or higher toxicities observed. The most common mild adverse events were pruritus (80%), rash (40%), and fatigue (40%), with single occurrences of other mild side effects such as hypothyroidism and anemia. <br /><br />In conclusion, the study suggests that nivolumab plus ipilimumab is an effective and safe alternative to chemotherapy for treating NSCLC in elderly patients, irrespective of PD-L1 expression. The absence of severe toxicities and the significant response rates highlight the potential of this regimen to offer durable outcomes in this patient demographic.

Keywords

nivolumab

ipilimumab

elderly patients

NSCLC

lung cancer

chemotherapy alternative

treatment efficacy

treatment safety

objective response rate

progression-free survival